We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+7.3%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.5B
AUM Growth
+$79.1M
Cap. Flow
+$24.7M
Cap. Flow %
1.64%
Top 10 Hldgs %
31.43%
Holding
99
New
7
Increased
27
Reduced
26
Closed
7

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$14.3M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.9M
3
INSP icon
Inspire Medical Systems
INSP
+$11.3M
4
DHR icon
Danaher
DHR
+$11.2M
5
OLMA icon
Olema Pharmaceuticals
OLMA
+$10.4M

Top Sells

Rank Stock Value
1
ABT icon
Abbott
ABT
+$13.6M
2
TMO icon
Thermo Fisher Scientific
TMO
+$9.99M
3
ELV icon
Elevance Health
ELV
+$9.26M
4
BIIB icon
Biogen
BIIB
+$9M
5
RVNC
Revance Therapeutics, Inc.
RVNC
+$8.91M

Sector Composition

Rank Sector Weight
1 Healthcare 97.82%
2 Industrials 1.29%
3 Technology 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OLMA icon
76
Olema Pharmaceuticals
OLMA
$1.04B
$4.7M 0.31%
+500,000
New +$10.4M
VRAY
77
DELISTED
ViewRay, Inc.
VRAY
$4.12M 0.27%
775,000
– –
RIGL icon
78
Rigel Pharmaceuticals
RIGL
$778M
$4.07M 0.27%
152,000
– –
MYOV
79
DELISTED
Myovant Sciences Ltd.
MYOV
$4.02M 0.27%
250,000
– –
VCRA
80
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$3.84M 0.26%
+60,000
New +$3.37M
PHAT icon
81
Phathom Pharmaceuticals
PHAT
$693M
$3.62M 0.24%
186,210
– –
GTHX
82
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$3.4M 0.23%
325,000
– –
IMCR icon
83
Immunocore
IMCR
$1.73B
$3.07M 0.2%
90,000
– –
ANNX icon
84
Annexon
ANNX
$883M
$2.9M 0.19%
250,000
– –
KYNB
85
Kyntra Bio
KYNB
$28.2M
$2.82M 0.19%
8,000
– –
OLK
86
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$2.62M 0.17%
140,000
– –
IONS icon
87
Ionis Pharmaceuticals
IONS
$9.46B
$2.29M 0.15%
75,000
– –
RPID icon
88
Rapid Micro Biosystems
RPID
$85.2M
$2.09M 0.14%
+196,087
New +$3.06M
PVLA
89
Palvella Therapeutics
PVLA
$2.19B
$1.18M 0.08%
3,750
– –
INNV icon
90
InnovAge Holding
INNV
$1.48B
$741K 0.05%
150,000
– –
EPZM
91
DELISTED
Epizyme, Inc
EPZM
$702K 0.05%
265,000
– –
DCPH
92
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$604K 0.04%
60,000
– –
BMY icon
93
Bristol-Myers Squibb
BMY
$132B
– –
-125,000
Closed -$7.4M
FLNA
94
Filana Therapeutics
FLNA
$48.2M
– –
-85,000
Closed -$5.28M
SPRY icon
95
ARS Pharmaceuticals
SPRY
$587M
– –
-150,000
Closed -$1.5M
RVNC
96
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-320,000
Closed -$8.91M
RDUS
97
DELISTED
Radius Health, Inc.
RDUS
– –
-430,000
Closed -$5.34M
ARNA
98
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-60,000
Closed -$3.57M
XLRN
99
DELISTED
Acceleron Pharma
XLRN
– –
-4,392
Closed -$756K
1 2 3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2021 Portfolio in Review

As of Q4 2021, Rhenman & Partners Asset Management held 99 positions worth $1.5B, up 5.6% from $1.42B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management's Q4 2021 filing shows 7 new, 27 increased, 26 reduced and 7 closed positions. Its largest new stake was Inspire Medical Systems: 46,373 shares worth $10.7M. The largest sale was Abbott, an estimated $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Industrials and Technology.

  • Rhenman & Partners Asset Management's largest Q4 2021 buy was Inspire Medical Systems: 46,373 shares worth $10.7M.
  • Rhenman & Partners Asset Management added most to Boston Scientific in Q4 2021, an estimated $14.3M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2021 reduction was Abbott, cutting an estimated $13.6M.
  • Rhenman & Partners Asset Management fully exited Revance Therapeutics, Inc. in Q4 2021, selling an estimated $8.91M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $1.5B portfolio in Q4 2021.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 7 in Q4 2021.
  • Rhenman & Partners Asset Management's portfolio value rose 5.6% quarter-over-quarter to $1.5B.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.